Sanofi and the Institut Pasteur create four prestigious awards

SanofiSanofi (EURONEXT: SAN and NYSE: SNY) and the Institut Pasteur announced the creation of the Sanofi-Institut Pasteur Awards to encourage scientific excellence in the service of health.

Four hundred and eighty thousand euro (480,000 €) will support four innovative research projects demonstrating real progress in the life sciences and providing answers to major healthcare problems, more specifically in four fields: neglected tropical diseases, vaccine innovation, drug resistance, and therapeutic approaches to ageing and regenerative medicine.

The jury is composed of seven prestigious members: Prof. Peter C. Agre, John Hopkins University, Baltimore, United States, Nobel Prize in Chemistry 2003, Prof. Elizabeth H. Blackburn, University of California, San Francisco, Nobel Prize in Medicine 2009, Prof. Pascale Cossart, Head of the Bacteria-Cell Interactions Unit, Institut Pasteur, Prof. Alice Dautry, President of the Institut Pasteur, Prof. Depei Liu, Vice President of the Academy of Engineering of China and President of the Chinese Academy of Medical Sciences and the Peking Union Medical College, Dr Robert Sebbag, Vice President, Access to Medicines, Sanofi, and Dr Elias Zerhouni, President, Global R&D, Sanofi.

"With these awards, the Institut Pasteur confirms its commitment to the greater interest by encouraging research, notably in conditions affecting the most vulnerable populations and diseases sharply on the rise in the world," said Alice Dautry, President of the Institut Pasteur.

"I am enthusiastic about this collaborative endeavour with the Institut Pasteur which will promote and support research teams capable of making a real difference in the lives of patients and in key areas of public health," said Elias Zerhouni, President, Global R&D of Sanofi. "The Sanofi-Institut Pasteur Awards follow a long-standing partnership between our two organizations."

Candidates can submit their applications by April 20, 2012. The prices will be awarded in November 2012 at the Institute Pasteur in Paris. For further information: www.sanofiinstitutpasteur-awards.com

Sanofi and the Institut Pasteur have a long history of partnership which reflects Louis Pasteur philosophy which states that "Pure research and applied research are not separate entities. Research and its applications are united together as the fruit of the tree is united with the branch that bears it."

The first partnership emerged through the establishment of the dedicated fund "Fighting Parasitic Diseases" which led to the creation of new research teams. Today, Sanofi also sponsors the Center for Integrative Biology of Emerging Diseases (BIME) and collaborates with the Institut Pasteur in the development of new vaccines against infectious diseases.

About the Institut Pasteur
An internationally renowned center of biomedical research, the Institut Pasteur, created in 1887 by Louis Pasteur, is a recognized private non-profit foundation. Its mission is to contribute to preventing and fighting disease in France and around the world, through scientific and medical research, education, and public health activities. About 2600 individuals work on its campus in Paris. In addition to research in the field of life sciences, a significant part of its work is dedicated to the study of infectious, genetic and neurodegenerative diseases as well as certain cancers. The Institut Pasteur is at the heart of an international network comprising 32 institutes on 5 continents. Since its creation, 10 researchers have received the Nobel Prize in Medicine.

About Sanofi
Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets and animal health. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Most Popular Now

Sanofi to acquire Ablynx for €3.9 Billion

Sanofi and Ablynx, a biopharmaceutical company engaged in the discovery and development of Nanobodies®, entered into a definitive agreement under which Sanofi will offer ...

In wine, there's health: Low levels of alcohol goo…

While a couple of glasses of wine can help clear the mind after a busy day, new research shows that it may actually help clean the mind as well. The new study, which appe...

Repurposed drug found to be effective against Zika…

In both cell cultures and mouse models, a drug used to treat Hepatitis C effectively protected and rescued neural cells infected by the Zika virus - and blocked transmiss...

More stroke patients may receive crucial treatment…

More patients could be eligible for critical treatments to remove or dissolve blood clots that cause strokes, according to a new treatment guideline issued by the America...

Drug trial protocol redactions by industry sponsor…

New research published by the Journal of the Royal Society of Medicine exposes the extent of redactions in protocols for industry-sponsored randomised drug trials. Trial ...

Interim publications of randomized trials make new…

Early results from randomized trials are sometimes published before the trial is completed. The results of such interim publications may generate a great deal of interest...

Advanced Accelerator Applications receives FDA ap…

Novartis AG (NYSE: NVS) announced that Advanced Accelerator Applications, a subsidiary of Novartis Groupe S.A., has received US Food and Drug Administration (FDA) approva...

Blood vessel-on-a-chips show anti-cancer drug effe…

Researchers at the Institute of Industrial Science (IIS), the University of Tokyo, CNRS and INSERM, report a new organ-on-a-chip technology for the study of blood vessel ...

Roche reports good results in 2017

In 2017, Group sales rose 5% to CHF 53.3 billion. Core operating profit grew 3% and Core EPS increased 5%, reflecting the good underlying business performance. On an IFRS...

FDA approves new treatment for certain digestive t…

The U.S. Food and Drug Administration today approved Lutathera (lutetium Lu 177 dotatate) for the treatment of a type of cancer that affects the pancreas or gastrointesti...

Cells of 3 advanced cancers die with drug-like com…

Researchers at Southern Methodist University have discovered three drug-like compounds that successfully reverse chemotherapy failure in three of the most commonly aggres...

Pfizer announces positive top-line results for pot…

Pfizer Inc. has announced that REFLECTIONS B3281006, a comparative safety and efficacy study of PF-05280586 versus MabThera® (rituximab-EU), met its primary endpoint. PF-...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]